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AbstrAct
COPD is characterised by tissue destruction and 
inflammation. Given the lack of curative treatments and 
the progressive nature of the disease, new treatments 
for COPD are highly relevant. In vitro cell culture and 
animal studies have demonstrated that mesenchymal 
stromal cells (MSCs) have the capacity to modify immune 
responses and to enhance tissue repair. These properties 
of MSCs provided a rationale to investigate their 
potential for treatment of a variety of diseases, including 
COPD. Preclinical models support the hypothesis that 
MSCs may have clinical efficacy in COPD. However, 
although clinical trials have demonstrated the safety of 
MSC treatment, thus far they have not provided evidence 
for MSC efficacy in the treatment of COPD. In this review, 
we discuss the rationale for MSC-based cell therapy 
in COPD, the main findings from in vitro and in vivo 
preclinical COPD model studies, clinical trials in patients 
with COPD and directions for further research. 
IntroductIon
Mesenchymal stromal cells (MSCs) are cells of 
non-haematopoietic origin, with the capacity to 
differentiate into multiple lineages of the mesen-
chyme, that is, chondrocytes, osteoblasts and 
adipocytes. Although an absolute definition of 
MSCs is not available, the currently used working 
criteria from the International Society for Cellular 
Therapy suggest defining MSCs on isolation by 
(i) their adherence to plastic; (ii) expression of 
CD73, CD90 and CD105 on their cell surface; (iii) 
absence of several haematopoietic and endothelial 
markers (ie, CD45, CD34, CD11b or CD14, CD79 
or CD19 and HLA-DR in human MSCs).1 Unique 
MSC-specific markers have not yet been identified, 
and MSCs constitute a heterogeneous cell popula-
tion, including both multipotent (stem) cells and 
progenitor cells and might even contain pluripotent 
cell fractions.2 MSCs were first described in the 
bone marrow where they constitute a small fraction 
of cells (0.001%–0.01%) that closely interact with 
haematopoietic cells to support haematopoiesis and 
skeletal homeostasis.3 4 Since then, it has become 
evident that MSCs reside in many tissues, including 
mesenchymal tissues (bone, adipose tissue, connec-
tive tissue), umbilical cord and several organs 
including the liver, spleen and lung.5 Functional in 
vitro assays indicate different physiological roles of 
MSCs related to their heterogeneity and tissue loca-
tion of origin.6–8
On infusion, culture-expanded MSCs regulate 
inflammatory and immune responses and tissue 
repair. Following early observations that MSCs 
inhibit T-cell proliferation,9 MSCs were found to 
interact with the majority of innate and adaptive 
immune cells.10 MSCs can respond to local trig-
gers, such as inflammatory cytokines and patho-
gen-associated and damage-associated molecular 
patterns. These triggers functionally mature MSCs 
towards either a pro-inflammatory or anti-inflam-
matory phenotype to regulate inflammation.11 12 
MSCs furthermore contribute to tissue homeostasis 
through anti-apoptotic and regenerative proper-
ties.13 These various effects can be mediated via 
cell-to-cell interactions and secretion of soluble 
factors including growth factors, matrix proteins 
and cytokines, and through mitochondrial transfer 
and secretion of extracellular vesicles.14 15 Finally, 
transdifferentiation and engraftment of MSCs 
into local tissue have been described,16 17 but it is 
unclear to which extent this contributes to putative 
repair-enhancing activities of infused MSCs.
These largely preclinical observations suggest 
that MSCs exert a wide range of activities that may 
be beneficial clinically, but how they relate to MSC 
activity in humans is incompletely understood. The 
first clinical trials in the late 90s18 assessed safety 
of MSCs in non-haematopoietic diseases. The clin-
ical potential of MSCs was put in the spotlight by 
a landmark case report by Le Blanc et al in 2004, 
indicating MSC efficacy on immune restoration in a 
paediatric patient with refractory graft-versus-host 
disease.19 This boosted the interest in MSC-based 
cell therapy for a variety of diseases characterised 
by dysregulated immune responses (inflamma-
tion) and/or by tissue damage (eg, ischaemic heart 
disease, spinal cord injury, osteogenesis imperfecta). 
In 2016, a phase III clinical trial reported posi-
tive results for the treatment of therapy-resistant 
complex perianal fistulas in Crohn’s disease.20 Thus 
far, clinical trials have indicated that MSC admin-
istration is safe and have shown promising results 
in immune-related disorders but mixed results 
regarding the clinical benefit in other diseases.21 22 
The field is cautiously advancing towards place-
bo-controlled trials to further evaluate the efficacy 
of MSCs and research is ongoing to improve treat-
ment efficacy and study the therapeutic potential of 
MSCs in other patient groups.
Preclinical data indicate effectiveness of MSCs 
for treatment of a variety of respiratory diseases, 
including pulmonary hypertension, asthma, bron-
chiolitis obliterans, idiopathic pulmonary fibrosis 
(IPF), acute respiratory distress syndrome (ARDS) 
and bronchopulmonary dysplasia (BPD).23–25 Clin-
ical trials in so far limited numbers of patients with 
IPF, ARDS or BPD have revealed that administration 
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of MSCs (intravenous or intratracheal) is safe but have not yet 
demonstrated clinical benefit from MSC administration.26–28 
Because COPD is characterised by inflammation, airway remod-
elling and destruction of lung architecture,29 the clinical poten-
tial of a cell population that can induce an anti-inflammatory, 
regenerative environment seems obvious. Indeed, supported by 
preclinical studies and based on promising results in immune 
diseases, MSCs have already been investigated in patients with 
COPD. Here, the data from these (pre)clinical studies using 
MSC-based cell therapy will be summarised, subdivided by data 
from in vitro, in vivo and clinical studies. Cell therapy studies 
using bone marrow cells that were not further cultured and/or 
selected before administration are not discussed in this review.
EffEcts of Mscs In lung Injury ModEls In vItro
This section will provide a non-exhaustive overview of in vitro 
studies focussing on effects of MSCs on inflammation and repair 
using lung epithelial or endothelial cell injury models. For a 
broader perspective on the anti-inflammatory, regenerative and 
paracrine effects of MSCs, we refer to the reviews by  (Uccelli 
and de Rosbo,10 Murphy et al.11 and Liang et al.14). 
Anti-inflammatory effects
Anti-inflammatory effects of MSCs have been extensively studied 
in vitro.10 These include effects of MSCs on cells of the innate 
and adaptive immune system, and modulation of the balance 
between proteases and protease inhibitors. Immunomodulating 
effects of MSCs include inhibition of T-cell and B-cell prolifera-
tion, induction of regulatory B-cells and T-cells and skewing of 
monocyte/macrophage and dendritic cells to anti-inflammatory 
and tolerogenic phenotypes. These effects are exerted through 
direct cell-to-cell contact (eg, via programmed death-1 for 
MSC and T-cell interactions), changes in amino acid and lipid 
metabolism through indolamine 2,3-dioxygenase expression 
and COX2-mediated prostaglandin E2 (PGE2) production and 
secreted factors including transforming growth factor-β (TGF-β) 
and hepatocyte growth factor (HGF). Recent data suggest that 
phagocytosis of apoptotic MSCs by macrophages, and subse-
quent polarisation to an alternative macrophage phenotype 
contributes to their immunoregulatory effects.30 31 MSCs were 
also found to induce expression of secretory leucocyte protease 
inhibitor in elastase-treated lung epithelial cells via MSC-se-
creted epidermal growth factor (EGF) and HGF.32 This response 
is likely beneficial, especially in COPD, as protease inhibitors 
counteract protease-mediated tissue injury and degradation of 
protective mediators.33 In cocultures with cigarette smoke extract 
(CSE)-stimulated macrophages, MSCs increased the viability of 
macrophages and decreased their expression of the pro-inflam-
matory mediators cyclooxygenase 2 (COX2), interleukin (IL)-6 
and inducible nitric oxide synthase, whereas secretion of the 
anti-inflammatory cytokine IL-10 was induced.34 Collectively, 
these properties of MSCs may be beneficial in COPD.
Antimicrobial effects
In addition to their anti-inflammatory effects, antimicrobial 
effects are also ascribed to MSCs.35–37 These include direct inhib-
itory effects of MSCs on bacterial growth and indirect effects via 
secretion of immune-mediators that activate other (inflamma-
tory) cells. Indeed, MSCs and MSC-derived conditioned medium 
directly reduce the growth rate and survival of several respira-
tory pathogens (Pseudomonas aeruginosa, Staphylococcus aureus 
and Streptococcus pneumoniae),38 which was in part attributed 
to the secretion of antimicrobial peptides.35 39–41 Indirect effects 
of MSCs on host defence may be mediated by secretion of 
immune-mediators such as IL-6, IL-8, granulocyte-macrophage 
colony-stimulating factor and macrophage migration inhib-
itory factor, which recruit neutrophils and enhance neutro-
phil antimicrobial activity.42 Both direct and indirect effects of 
MSCs may thus contribute to host defence responses towards 
invading pathogens, which may be relevant for preventing or 
treating COPD exacerbations as these significantly contribute to 
morbidity and mortality in patients with COPD.
lung epithelial and endothelial repair
In vitro models of lung epithelial and endothelial injury have 
demonstrated that MSCs can prevent injury and restore 
damaged monolayers. These models included scratch wound 
assays and electroporation of monolayers to assess effects of 
MSCs on wound closure and barrier function, or the addition 
of stimuli relevant in COPD pathogenesis, such as CSE, elastase, 
papain or pro-inflammatory cytokines or bacterial products such 
as lipopolysaccharide (LPS). Using these models, MSCs as well 
as MSC-conditioned medium (MSC-CM) were shown to induce 
repair and to protect against airway epithelial cell damage. 
MSCs and MSC-CM enhanced wound closure in scratch 
wounds in the A549 alveolar epithelial cell line and in primary 
small airway epithelial cells, possibly by increasing migration 
and proliferation of epithelial cells.43 44 MSCs or unstimulated 
MSC-CM were also found to increase proliferation in lung 
epithelial cells injured by exposure to CSE or pro-inflammatory 
cytokines, suggesting a protective effect of MSCs.45 46 Similar 
results were obtained in NCI-H292 airway epithelial cells47 
and in (human umbilical vein) endothelial cells,48–50 including 
observations that adipose-tissue-derived stromal cell (AT-MSC) 
conditioned medium restored endothelial barrier function 
following CSE exposure.49 Furthermore, MSCs reduced apop-
tosis in pulmonary cell cultures derived from papain-treated 
mice and in CSE-stimulated endothelial cells.50 51 The potential 
mechanisms that underlie these effects are partially attributed 
to MSC-secreted factors: secretion of IL-6, IL-8 and chemo-
kine (C-X-C motif) ligand 1 by MSCs was found to enhance 
A549 alveolar epithelial cell migration,44 keratinocyte growth 
factor (KGF) secretion-induced epithelial cell proliferation46 
and reduction of the number of apoptotic cells was linked to 
vascular endothelial growth factor (VEGF)-A50 51 and HGF.52 
It was furthermore suggested that MSCs support epithelial cell 
attachment and spreading via secretion of extracellular matrix 
proteins.43 53 Finally, the observation that mitochondrial transfer 
from MSCs to airway epithelial cells may protect against ciga-
rette smoke-induced injury is of special interest in view of the 
increasing number of reports on mitochondrial dysfunction in 
COPD.54 This non-exhaustive list of factors constitutes only 
a small fraction of the factors secreted by MSCs55 and future 
investigations are expected to further elucidate factors involved 
in MSC-mediated wound repair in vitro.
Preconditioning of Mscs
Preconditioning of MSCs, for example, with pro-inflammatory 
cytokines or hypoxic culture conditions was found to polarise 
MSCs towards an anti-inflammatory profile (referred to as 
MSC2) and to enhance their therapeutic potential in various 
disease models.56 In line with this, preconditioning of MSCs 
had favourable effects on lung epithelial repair. Our own data 
show that preconditioning of MSCs with tumour necrosis factor 
(TNF)-α and IL-1β induced the expression of several growth 
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epithelial cells.47 Similarly, TNF-α, IL-6 and IL-1β-stimulated 
MSCs induced A549 alveolar epithelial cell proliferation via 
increased KGF secretion.46 Increased secretion of other growth 
factors, that is, VEGF, fibroblast growth factor 2, insulin-like 
growth factor 1 and HGF, in response to stimulation with 
TNF-α, LPS or hypoxia was also shown, but functional effects 
were not assessed.57 Furthermore, mediators that are released 
by damaged alveolar epithelial cells increased the migration of 
MSCs and amniotic fluid-derived stem cells.43 58 Overall, these 
data indicate that inflammatory mediators that are present in 
areas of tissue damage can alter the secretome of MSCs in such a 
way that it promotes wound repair. Theoretically, this inflamma-
tion-induced conditioning could enhance their effects in COPD, 
which is characterised by tissue damage and inflammation.59
In summary, in vitro studies show that MSCs exert a range 
of anti-inflammatory and immunomodulatory effects relevant to 
COPD, including improved protease/protease inhibitor balances, 
interactions with macrophages and antimicrobial effects. In 
addition, MSCs enhance wound healing in lung epithelial and 
endothelial cell models in vitro by increasing proliferation 
and migration and reducing apoptosis. The observation that 
MSC-CM exerts similar effects as MSCs supports the paracrine 
actions of MSCs, but many of the active factors still need to 
be elucidated. Furthermore, future investigations should focus 
on preconditioning of MSCs to enhance their regenerative and 
migratory potential.
EffEcts of Mscs on coPd ModEls In vIvo
The first animal study assessing the effects of MSC-based cell 
therapy in COPD showed promising results. Shigemura et al 
used porcine pancreatic elastase (PPE) to induce emphysema in 
rats, followed by intravenous administration of AT-MSCs (plastic 
adherent, CD44+/CD90+/CD45−) on day 7. After 14 days, MSC 
treatment resulted in restoration of both alveolar and endothelial 
structures in AT-MSC-treated rats compared with control rats as 
shown by immunohistochemical analysis. A significant increase 
in proliferating cells and significantly lower numbers of apop-
totic cells were observed in the treatment group. Additionally, 
improved gas exchange and exercise tolerance was observed.60
Following this initial encouraging observation, several studies 
have investigated in vivo effects of MSCs in experimental 
models of COPD and emphysema, mainly in rats and mice. A 
variety of protocols was used to induce COPD-like features 
(table 1), including instillation of proteolytic enzymes (PPE or 
papain) or chronic exposure to cigarette smoke with or without 
additional LPS. Administered MSCs were usually species-related 
allogeneic MSCs from the bone marrow or adipose tissue, but 
other sources of MSCs (amniotic fluid, lung or human) were 
also investigated. They were either administered systemically 
or locally via intratracheal instillation, with notable variation in 
frequency, dosage and timing of administration as well as in the 
period allowed to assess effects (see table 1 for details on study 
protocols). This variability complicates drawing generalisable 
conclusions on treatment regimens, although it is apparent that 
cell source and numbers, route of administration and timing of 
administration affect outcome.52 61–64 Importantly, low doses of 
MSCs already improved lung architecture, and MSCs were still 
effective when administered as a late treatment in established 
emphysema, although there appeared to be a time-dependent 
decrease in effectiveness.52
The initial observation by Shigemura et al60 showing that 
MSC-based cell therapy improves lung architecture, decreases 
apoptosis and increases cell proliferation was confirmed by 
several subsequent in vivo studies,45 50 54 61 65-67 and a meta-anal-
ysis.68 The exact mechanisms responsible for this repair have 
not yet been fully elucidated. The large body of circumstantial 
evidence is summarised in this section on in vivo COPD models, 
with a particular focus on effects of MSCs on inflammation and 
repair (see figure 1 for a schematic overview and table 1 for 
details on study protocols).
Anti-inflammatory effects
COPD is characterised by an enhanced inflammatory response,29 
and assessment of MSC-mediated effects on inflammation is 
therefore relevant. Assessment of the effect of MSC treatment 
on inflammation in in vivo studies mostly included immunohis-
tochemical evaluation of pulmonary inflammatory infiltrates, 
bronchoalveolar lavage fluid (BALF) analysis of inflammatory 
cells and cytokines and analysis of mRNA expression of inflam-
matory cytokines in lung tissue.
MSC treatment reduced inflammatory cell infiltrates in 
peribronchiolar, perivascular and alveolar septa in lung tissue 
compared with control,34 50 61 69 and a relative increase in alter-
natively activated (or M2) macrophages was observed.34 61 This 
increased abundance of macrophages with an anti-inflamma-
tory phenotype may contribute to reducing inflammation and 
enhancing repair responses.70 One study showed no decrease in 
inflammatory parameters on MSC administration in an emphy-
sema model of chronic LPS exposure.71 In BALF, the total 
number of inflammatory cells and its subsets, that is, macro-
phages, neutrophils and lymphocytes, were lower in MSC-treated 
animals,63 66 69 whereas there was a relative increase in type 
2 macrophages.34 BALF analysis of inflammatory cytokines 
involved in COPD pathogenesis showed a significant reduction of 
IL-1β, TNF-α and KC (murine IL-8 homologue) concentrations 
following MSC treatment,32 63 although other studies did not 
observe such effects.71 72 In line with decreased BALF-cytokine 
concentration, decreased mRNA expression of these cytokines 
were observed in emphysematous lung tissue following MSC 
treatment,32 50 52 61 69 but results for monocyte chemoattractant 
protein 1 were conflicting.50 69 Besides, treatment with MSCs 
decreased concentrations of several matrix metalloproteinases 
(MMPs), that is, MMP2, MMP9 and MMP12.50 Although 
MMPs are important regulators of extracellular matrix homeo-
stasis, abundance of MMPs has been linked to tissue destruction 
in emphysema73 suggesting that decreased levels may contribute 
to tissue homeostasis.
Only limited in vivo data are available concerning potential 
mechanisms of action of MSCs. MSCs are thought to attenuate 
inflammation via reduction of COX2 expression and PGE2 
synthesis by macrophages34 and decreased expression of TNF-α 
is attributed in part to an MSC-mediated increase in TGF-β 
secretion by macrophages.69 It is furthermore hypothesised that 
induction of TGF-β signalling by MSCs inhibits MMP9 and 
MMP12 expression in alveolar macrophages.50
In conclusion, administration of MSCs appears to dampen 
inflammation in animal models of emphysema, reflected by 
a decrease in cytokine concentrations, inflammatory cells 
and infiltrates in lung tissue. There appears to be a role of 
MSC-mediated changes in macrophage polarisation towards 
alternatively activated type 2 macrophages, likely contributing 
to dampening of inflammation, but effects of MSCs on other 
immune cells were not systematically investigated. Further-
more, the precise mechanisms of action of MSCs in vivo are 
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table 1 Animal models investigating MSCs in COPD: methods and main outcomes
Author
(year) Model






effects (from last 












7 days All sources improved MLI, reduced inflammation and 
apoptosis. AT-MSC and BM-MSC improved mPAP and 
increased VEGF. Change of macrophages from M1 to 











28 days Improved MLI and reduced inflammation (including 
increased M2 macrophages in BALF) through 











9 weeks Improved MLI and PFT, reduction of pro-
inflammatory mediators and proteases, reduced 






0.5 and 1.0×106 IV (1), 
0.33×106 IV (2)
Week 6 or 7, once (1)
Twice-weekly, thrice 
(2)
22 (1) or 28 (2) 
days
Both sources improved MLI and increased IL-6 levels. 
No evidence of transdifferentiation. LR-MSC showed 












1, 7, 14, 28 days 
(BMC) and 8 weeks
Improved MLI and vascular parameters (mPAP, 
numbers of small pulmonary vessels), increased 












28 days Increased tissue mass on CT with increased lung 
perfusion and ECM content. Only a fraction of LR-
MSCs appeared to engraft. Proposed mechanism: 
promoted outgrowth of epithelial and endothelial 









7, 14 and 21 days Improved MLI, increased levels of HGF, EGF and 
SLPI. Proposed mechanism via paracrine factors; 
infrequent engraftment or differentiation into 
epithelial cells.
Kennelly, et al52 
(2016)
NOD/SCID/IL-2Rγnull mice
IN PPE 6 times
2 weeks
BM-MSC (human)
0.5×106 IV or MSC-CM
Day 0 (1), 7 (2) or 12 
(3) or day 0 (CM)
Once
14 (1), 7 (2) or 16 
(3) days or 14 days 
(CM)
Dose-dependent, protective effects of MSCs: 
decreased inflammation, less apoptosis and fibrosis. 
CM is protective but less effective. Proposed 






BM-MSC 0.5×106 IV Week 14, 16, 18, 20
4 times
7 days No effect on lung function parameters, MLI, lung 
tissue remodelling, pulmonary inflammatory 









7 days Dose finding: improved MLI and increased VEGF with 
0.05×106 MSCs. No effects on apoptosis, MMPs, SLPI, 









Day 29 and 43
Twice
14 days Both sources improved MLI, but iPSC-MSCs 
were more effective which is ascribed to higher 










20 and 40 days Improved MLI, less apoptosis of AT2 cells, increased 
expression of SPA, SPC and TTF1. Proposed 
mechanism: integration into lung tissue and 











14 days Improved MLI, decreased apoptosis and 
inflammation, increased proliferation. No effects on 








1×106 intranasal or 
intraperitoneal 
Day 60 and 67
Twice
9 days Laser-irradiated MSCs resulted in less inflammation, 
mucus production, collagen accumulation and tissue 
damage. Proposed mechanism: reduced NF-κB and 
NF-AT activation and increased IL-10.
Schweitzer, et al 49
(2011)
DBA/2J and C57BL/6 mice
CS exposure 2 (1), 24 weeks 
(2) or VEGFR-inh (3)
AT-MSC (human)
0.3×106 IV
Day 14 once (1), 
month 2–4 twice-
weekly, 4 times (2) or 
day 3 once (3)
1, 7, 21 days (1); 
1 day (2) or 3 and 
25 days (3)
Reduced inflammatory infiltration, decreased lung 
cell death and airspace enlargement. Effects on bone 









7, 14, 21 and 
28 days
Increased HGF. Inhibition of alveolar cell apoptosis, 
enhancement of epithelial cell proliferation and 
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lung tissue repair
Tissue destruction in emphysema is characterised by a loss 
of alveolar attachments, and MSC treatment was found to 
restore damaged alveolar structures in animal models of 
emphysema, reflected by a decrease in the mean linear inter-
cept (a measure that describes the mean free distance in air 
spaces),32 34 45 49–52 54 61 65–67 74 although this was not shown in 
chronic LPS-induced tissue destruction.71 In some of these 
studies, MSCs were administered during induction of emphy-
sema, suggesting that inhibition of emphysema development 
may have contributed to the effects (table 1). The observed resto-
ration of damaged alveolar tissue is likely related to a decrease 
in numbers of apoptotic cells, usually assessed using TUNEL 
assays or by measuring caspase-3 concentrations45 49 50 52 60 61 65-67 
and to increased numbers of proliferating cells, that is, Ki67+ 
or PCNA+ cells.45 60 66 Besides, an MSC-induced reduction in 
collagen deposition was observed in elastase-induced emphy-
sema, suggesting antifibrotic effects that may contribute to inhi-
bition of airway remodelling in COPD.52 Factors that contribute 
to MSC-mediated tissue repair are described in the following 
section.
Paracrine effects
Administration of MSC-CM induced protective effects on lung 
tissue architecture,45 52 in line with the concept that MSCs exert 
their effects in part via paracrine signalling, including secretion of 
growth factors. Indeed, following MSC administration, mRNA 
expression of HGF,32 60 EGF,32 VEGF49–51 60 and KGF45 was 
increased in emphysematous lung tissue compared with control. 
These growth factors are thought to contribute to restoration of 
tissue architecture in the lung,75 and HGF in specific was linked 
to anti-apoptotic effects of MSCs.52 The increased concentra-
tions of HGF appeared to result from a combination of secre-
tion by MSCs and induced secretion by local cells,60 whereas 
for the other growth factors this was undetermined. Conflicting 
data were obtained for the effect of MSCs on TGF-β secre-
tion.50 61 However, the relevance and contribution of TGF-β in 
the context of COPD is unclear, as TGF-β has been linked both 
to small airway fibrosis in COPD76 as well as to dampening of 
immune responses.69
Effects on endothelium
Endothelial integrity is essential for maintenance of the alve-
olar-capillary unit, with a pivotal role for VEGF signalling.77 
VEGF-receptor blocking can induce apoptosis of endothelial 
cells and emphysema, and treatment with human AT-MSCs can 
abrogate this effect.49 Others have also demonstrated a lowering 
in destruction and apoptosis of endothelial cells following MSC 
treatment in cigarette or PPE-induced emphysema.50 61 Func-
tional effects include higher numbers of pulmonary capillaries 
corresponding with increased perfusion of the lung,60 and 
reduced pulmonary artery pressure.45 61
Engraftment and transdifferentiation into lung structural cells
Engraftment and transdifferentiation of MSCs in epithelial 
cells have been proposed to contribute to the reconstruction of 
destructed lung architecture in emphysema. To address this, a 
number of animal studies have used green-fluorescent labelling 
of MSCs or administration of MSCs from male donors to female 
recipients, allowing detection of the Y-chromosome. MSCs 
were thus found to engraft into the lung tissue within 24 hours 
after administration, but their numbers appear to be low and 
decrease in a time-dependent fashion.32 34 45 60 Although MSC 
engraftment and retention time in the lung can be increased 
following radiation67 72 or by using lung-resident MSCs,74 indi-
cations of functional benefits are lacking. Some studies provide 
evidence for transdifferentiation of MSCs into structural cells 
Author
(year) Model






effects (from last 










28 days Less pro-inflammatory cytokines and inflammatory 
cells in BALF, improved histopathology and airflow 







0.5×106 IT (1) or 
0.1×106 IV (2)
1 day prior, day 1 or 
day 21 (1); 30 min prior 
(2) once
19, 20 and 21 days MSCs IV inhibited deterioration of lung function, 
without effects on histology. IT administration of 












31 days Following SPA suicide gene system infusion: 
increased recruitment of MSCs with induction of 
pulmonary fibrosis, proposed mechanism: due to 










28 days Amelioration of emphysematous changes. MSC 
engraftment in recipient lungs and differentiation 









28 days Improved MLI, restoration of reduced VEGFA 
expression.
AF, amniotic fluid; AT-MSC, adipose tissue-derived stromal cell; AT2, alveolar type 2 cell; Autol., autologous; BALF, bronchoalveolar lavage fluid; BASCs, bronchoalveolar stem 
cells; BM, bone marrow; BMC, bone marrow cells; COX2, cyclooxygenase 2; CS, cigarette smoke; EB, endobronchial; ECM, extracellular matrix; EGF, epidermal growth factor; 
HGF, hepatocyte growth factor; IL, interleukin; inh, inhibition; iPSC, induced pluripotent stem cell; irr, irradiation; LPS, lipopolysaccharide; LR, lung resident (lung-derived); 
MLI, mean linear intercept; MMPs, matrix metalloproteases; mPAP, mean pulmonary artery pressure; MSC, mesenchymal stromal cell; MSC-CM, MSC conditioned medium; 
NF-AT, nuclear factor of activated T-cells; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NOD/SCID/IL-2Rγnull, non-obese diabetic/severe combined 
immunodeficiency IL-2 receptor gamma knockout; PFT, pulmonary function test; PGE2, prostaglandin E2; PPE, porcine pancreatic elastase; RB, retrobulbar; SD, Sprague Dawley; 
SLPI, secretory leucocyte protease inhibitor; SPA, surfactant protein A; SPC, surfactant protein C; T, tubal derived; TGF-β, transforming growth factor-β; TIMP, tissue inhibitor of 
metalloproteinases; TTF1, thyroid transcription factor 1; UC, umbilical cord; VEGFR, vascular endothelial growth factor receptor.
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of the alveolar unit,65 67 but these data could not be reproduced 
by others.32 74 The initial conclusions have been attributed to 
misinterpretation, and it should be concluded that evidence for 
direct contribution of MSCs to architectural reconstruction of 
destructed lung tissue is lacking.78
Collectively, these studies show that administration of MSCs 
restores lung architecture, decreases apoptosis and increases cell 
proliferation in animal models of emphysema. Several indicators 
of inflammatory responses are affected by MSCs, apparently in 
favour of dampening inflammation. Indirect evidence suggests 
that a regenerative environment is created via paracrine effects 
of MSCs and MSC-induced secretion of growth factors by local 
cells, resulting in higher concentrations of soluble factors that 
are relevant for tissue repair and that prevent apoptosis of endo-
thelial cells. MSC engraftment and differentiation on the other 
hand are not considered to deliver a relevant contribution to 
tissue repair (figure 1). However, it should be taken into account 
that these studies were designed to detect maximum effects of 
MSCs, predominantly used ‘acute’ models of emphysema and 
were variable regarding cell numbers, route and timing of MSCs 
administered. These issues require further investigation, particu-
larly in light of the fact that the clinical relevance of these preclin-
ical results still needs to be established, as will be discussed in the 
'Clinical trials' section.
clInIcAl trIAls
The interest in using MSCs for the treatment of COPD or emphy-
sema has translated into clinical trials. The first cell therapy study 
in COPD was an uncontrolled study in four subjects using autol-
ogous bone marrow mononuclear cells (BMMC) collected on 
treatment with granulocyte colony-stimulating factor.79 In view 
of the design, small size and lack of statistical analysis, no conclu-
sions can be drawn as to the efficacy of this treatment (despite 
reported changes in lung function and quality of life). Clearly the 
BMMC preparation used may have contained small numbers of 
MSCs, but this study cannot be viewed as an MSC intervention 
study. Since this review is focused on MSCs, cell therapy studies 
using bone marrow cells that were not further cultured and/or 
selected before administration are not further discussed. This 
section describes the main observations from clinical MSC trials, 
including an overview of ongoing trials (table 2). For more 
details, we refer to a recently published review on this topic.80
The first trial using MSCs in patients with moderate-to-se-
vere COPD (GOLD II-III) was conducted by Weiss et al: the 
safety and efficacy of treatment with four intravenous infusions 
of allogeneic bone marrow-derived MSCs (BM-MSCs) from a 
pool of non-HLA-matched donors (Prochymal) was compared 
with placebo in 62 patients, in a double-blind study. Infusions 
(100×106 cells/infusion) were well tolerated in all patients, and 
no clinically relevant adverse events related to the cell therapy 
were reported. Treatment with MSCs had no effect on clinical 
parameters, including pulmonary function and quality of life. 
There was a significant decrease in C reactive protein (CRP) 
levels up to 1 month after the first infusion. In the discussion, 
the authors suggest that effects of MSCs may have been missed 
due to the dosage and treatment regimen, sample size or due to 
figure 1 Mechanisms underlying the modulation of inflammation and lung tissue repair by MSCs in COPD. MSCs potentially act through cell-
to-cell contact, mitochondrial transfer and secretion of soluble factors (either directly secreted or in exosomes), including growth factors, (anti)-
inflammatory cytokines and chemokines (as indicated), thereby improving tissue homeostasis by favouring repair and dampening inflammatory 
responses. AMPs, antimicrobial peptides; CXCL1, chemokine (C-X-X motif) ligand 1; IDO, indolamine 2,3-dioxygenase; EGF, epidermal growth factor; 
ECMp, extracellular matrix proteins; GM-CSF, granulocyte macrophage colony-stimulating factor; HGF, hepatocyte growth factor; IFN-β, interferon-β; 
IL, interleukin; KGF, keratinocyte growth factor; MIF, migration inhibitory factor; MMP, matrix metalloproteinase; PGE2, prostaglandin E2; 
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the chronic nature of COPD, which might therefore be a less 
effective target for MSCs compared with more acute inflamma-
tory disorders, such as ARDS.81
The next clinical trial that investigated the safety of MSC 
administration in patients with severe-to-very severe COPD 
(GOLD III-VI) was conducted by our own group. The study 
protocol was designed around patients who were eligible for 
bilateral lung volume reduction surgery. Autologous MSCs 
(1–2×106 cells per kg bodyweight) were administered twice 
intravenously in between the two surgical interventions, which 
thus allowed comparison of lung tissue obtained before and 
after MSC administration. Seven patients completed the study 
protocol, without occurrence of therapy-related adverse events. 
Changes in FEV1 and bodyweight were attributed to the surgical 
intervention. The majority of analysed tissue parameters were 
unchanged in post-MSC tissue, except for increased CD3, CD4 
(T-cell markers) and CD31 (endothelial cell marker) expression. 
Although we cannot formally exclude surgery-related effects 
underlying these changes, as a control group is lacking, the 
observed increase in CD31 may be indicative of a reparative 
response. The increase in the endothelial marker CD31 is espe-
cially relevant in view of the observation that loss of endothelial 
integrity contributes to development of emphysema.82
Finally, a clinical trial designed to assess MSC effects on local 
inflammation resulting from endobronchial valve (EBV) place-
ment for severe-to-very severe COPD (GOLD III-IV) demon-
strated the safety of endobronchial instillation of allogeneic 
BM-MSCs (100×106 cells) prior to EBV placement, compared 
with saline-treated controls (five patients per group). In the MSC 
treatment group, serum CRP concentrations significantly improved 
up to 90 days follow-up.83 However, given the study design, this 
study cannot be viewed as one focused on MSC therapy for COPD.
At present, several trials evaluating cell therapy for the treat-
ment of COPD are still ongoing or their results are awaited 
(table 2). In view of the outcomes of the conducted clinical trials, 
it seems reasonable to optimise treatment protocols and iden-
tify relevant measurable outcome parameters for future clinical 
trials. However, the majority of these comprise (commercially 
initiated) safety trials, designed as open-label studies lacking 
a control group and will therefore likely add limited informa-
tion. Besides, it needs to be noted that most of these trials have 
not been reviewed or approved by relevant regulatory agencies 
and therefore caution is warranted when interpreting the data 
obtained from these trials. Apart from these registered trials, 
stem cell clinics in several countries offer unproven stem cell 
treatments with a variety of cells, including MSCs. To protect 
patients, the ATS RCMB Stem Cell working group has called 
for intensification of communication and collaboration between 
patients, scientists and respiratory disease societies worldwide to 
improve patient education, research and effective legislation.84
futurE dIrEctIons
There are several possible explanations for the lack of transla-
tion of the promising preclinical data of MSC treatment to clini-
cally relevant effects in patients with COPD. The animal models 
table 2 Clinical trials investigating MSCs for COPD treatment
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were optimised to detect maximum effects, and used higher cell 
numbers per kilogram bodyweight and more ‘acute’ models of 
COPD or COPD-like inflammation which can enhance MSC effi-
cacy. The available preclinical in vivo studies used invasive read-
outs for analysis, such as tissue resection and BALF, contrary to 
most clinical trials that investigated effects on minimally invasive 
clinical parameters, such as pulmonary function testing or quality 
of life assessment. Although relevant, these clinical read-outs 
might not be responsive to MSC therapy on short-term treat-
ment. It is therefore important to consider parameters that might 
change before clinical improvement. These may include induction 
of CD31 expression in lung tissue, as indicated by the data from 
our own institution,82 or alterations in the composition of inflam-
matory cells in sputum, BALF and lung tissue. Likewise, timing, 
duration, preconditioning, dosage and frequency of administra-
tion as well as the route of administration need to be optimised 
in humans. Although it can be argued that animal studies used 
higher doses of MSCs than human studies, thus explaining the 
lack of clinical efficacy in COPD, human clinical studies in osteo-
arthritis and Crohn’s disease suggest that the highest dose may 
not always provide the best results.85 86 These findings underscore 
the importance of dose finding in future clinical studies. Further 
research should clarify whether route of administration influences 
the potential of MSCs, and whether different routes should be 
used when aiming to target airway disease versus emphysema in 
COPD. Furthermore, an inflammatory environment appears to 
increase the potential of MSCs in vitro. This may have important 
implications for future research on the use of MSCs in the treat-
ment of COPD. First, as COPD is a chronic inflammatory disease, 
MSCs might be less effective in COPD compared with more acute 
inflammatory conditions such as ARDS. This might limit the ther-
apeutic potential of MSCs in stable COPD or have consequences 
for dosage and/or frequency of MSC administration. Besides, 
future studies should address the possibility that MSCs could be 
more effective in subgroups of patients with COPD with higher 
levels of inflammatory markers or during active inflammation 
(eg, during exacerbations). Second, this suggests that studies are 
needed to investigate the effect of preconditioning of MSCs with 
pro-inflammatory cytokines to improve their therapeutic poten-
tial in clinical COPD trials. In line with this, administration of 
MSCs engineered to overexpress mediators that increase their 
therapeutic potential, as for instance shown for MSCs overex-
pressing angiopoietin-1 or IL-10 which prevent ARDS in mice,87 88 
may hold promise for future applications. Finally, there is some 
evidence linking heterogeneity of MSCs to efficacy in vivo, and 
further studies are needed to identify ‘superior’ cell products to 
enhance the clinical efficacy of MSCs.89
It is evident that despite the encouraging preclinical data, a 
cure for COPD based on administration of MSCs is not yet at 
hand. It will take time and effort to elucidate the precise mode of 
action of MSCs. This may result in identification of biomarkers 
in patients with COPD that can serve as an early indicator that 
the progressive course of COPD is amended, which is essential 
to optimise treatment protocols. To reduce costs and limit the 
number of patients required to answer the unresolved questions, 
there is an urgent need for preclinical models that accurately 
reflect the human pathophysiology, for example, ex vivo lung 
perfusion, organoids, microfluidic lung-on-a-chip and lung 
tissue slices.
conclusIon
Preclinical studies suggest that cell therapy using MSCs is a 
potential new treatment strategy for COPD. Both in vitro and 
in vivo studies have demonstrated the regenerative potential of 
MSCs, which is reflected by their ability to induce airway epithe-
lial and endothelial repair, and restore lung tissue architecture in 
emphysematous lungs in animal models. These effects relate to 
increased proliferation and migration of target cells and reduc-
tion of apoptosis. Besides, MSCs modulate immune responses, 
dampen inflammatory responses in preclinical COPD models 
and affect protease/protease inhibitor balances favouring tissue 
homeostasis. The precise mechanisms are not fully unravelled, 
although the involvement of a number of secreted factors 
including cytokines and growth factors has been suggested. 
Whereas initial studies in a limited number of patients with 
COPD have revealed that MSC treatment is safe, so far there 
is no evidence for clinically relevant effects and further studies 
are needed to demonstrate that MSC-based treatments are of 
clinical relevance to patients with COPD. Important challenges 
need to be addressed, including optimising the MSC treatment 
regimens and identification of responsive outcome parameters, 
for example, in lung tissue. Such information may guide us in 
the choice of clinical outcome parameters for MSC treatment 
in patients with COPD. The lack of effective interventions to 
restore lung function in COPD will be an important driver for 
these and other innovative approaches to the treatment of this 
highly prevalent disease.
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